Zoetis Inc. (ZTS): Results of Operations and Financial Condition
Zoetis Inc. (ZTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99q22026.htm EX-99.1 Document EXHIBIT 99.1 Zoetis Announces Second Quarter 2026 Results • Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis • Adjusted Net In
How this was made
The 30-second read
Why it matters
The key tradable element is the full-year 2026 guidance revision: organic operational revenue growth (3)% to (1)% and adjusted net income organic operational growth (9)% to (5)%, alongside adjusted diluted EPS of $6.15-$6.25.
Market read
This is a primary earnings-and-guidance disclosure with explicit downside revisions, plus segment-level detail that can drive model changes and near-term positioning.
What to watch
US revenue fell 7% while International grew 6% organically; traders may be underweighting FX/geography mix and the potential for livestock and diagnostics to offset companion animal pressure.
Background
Zoetis filed an SEC 8-K (Item 2.02) with Exhibit 99.1 covering Q2 2026 financial results, segment performance, and multiple regulatory/product updates.
Ticker impact
Zoetis reported Q2 2026 results and revised full-year 2026 revenue guidance to $9.120-$9.320B and adjusted EPS to $6.15-$6.25.
Likely near-term downside bias as traders reprice full-year organic growth and adjusted EPS expectations; volatility possible around the guidance range.
The filing is a primary disclosure (8-K with Exhibit 99.1) containing fresh quarterly datapoints and explicit full-year guidance revisions, which typically drive earnings-model updates and positioning.
Market effects
Animal health peers may see read-across on companion animal demand softness and generic-competition impacts, while livestock strength could support selective optimism.
US segment weakness versus International growth may shift regional allocation and expectations for future product mix.
EU/UK approvals and US screwworm response highlight ongoing regulatory momentum, but near-term financial guidance dominates sentiment.
Counterpoint
Despite weaker guidance, the company cites a pipeline with more than 12 potential blockbusters and ongoing major-market approvals, which could limit long-term downside if investors overreact to one-year organic softness.
Key entities
- companyZoetis Inc.
Animal health company reporting Q2 2026 results and revising full-year 2026 revenue and adjusted EPS guidance.
- executiveKristin Peck
CEO quoted attributing pressure to softer companion animal clinic visits, price sensitivity, and heightened competition.
